Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Around 7% of the Indian population suffers from IBS
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
A significant proportion of healthcare professionals still tend to favor branded drugs
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Hepatitis B infects over 40 million people in India
Subscribe To Our Newsletter & Stay Updated